Prostate Cancer Clinical Trial
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
Summary
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.
Full Description
PRIMARY OBJECTIVES:
I. To collect multiparametric ultrasound (mp-US) data on 50 patients > 3 days prior to radical prostatectomy.
II. To correlate the imaging data with whole mount prostatectomy specimens in order to optimize mp-US with a machine learning approach.
OUTLINE:
Patients receive perflutren lipid microspheres intravenously (IV) over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres during ultrasound.
After completion of study, patients are followed up for 30 days.
Eligibility Criteria
Inclusion Criteria:
Subject must be scheduled for radical prostatectomy for treatment of prostate cancer
Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate prior to prostatectomy
Subject must be a male at least 18 years of age when informed consent is obtained
Exclusion Criteria:
Participant in a clinical trial involving an investigational drug within the past 30 days
Patients with known or suspected hypersensitivity to perflutren, PEG, or any other component of Definity
Previous treatment for prostate cancer, including hormone therapy
Clinically unstable, severely ill, or moribund as per treating physician
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19107, United States More Info
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.